Cerity Partners’s Protara Therapeutics TARA Stock Holding History

Cerity Partners’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,748	Closed	-$66.4K	–	3556
2026 Q1	$66.4K	Buy	+12,748	New	+$75.5K	﹤0.01%	3071

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Cerity Partners's TARA Position: Q2 2026 in Review

Cerity Partners sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 12,748 shares — an estimated $66.4K sold.

Cerity Partners first reported a position in TARA in Q1 2026 and held it in 1 quarter. The position peaked at $66.4K in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

Cerity Partners reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
Cerity Partners sold 12,748 Protara Therapeutics shares in Q2 2026, an estimated $66.4K.
Cerity Partners first reported a position in Protara Therapeutics in Q1 2026 and held it in 1 quarter.
Cerity Partners's Protara Therapeutics position peaked at $66.4K in Q1 2026.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.